Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 13/20 | 0.46 |
| ▸ | JAK3 | P52333 | 13/20 | 0.46 |
| ▸ | JAK1 | P23458 | 8/20 | 0.46 |
| ▸ | CDK4 | P11802 | 3/20 | 0.39 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
| ▸ | USP1 | O94782 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.36 |
| ▸ | MARK3 | P27448 | 1/20 | 0.34 |
| ▸ | MARK4 | Q96L34 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12371710 | 1.00 | JAK2 (0.46) | JAK2JAK3JAK1CDK4CDK6 | |
| SCHEMBL12371742 | 1.00 | JAK2 (0.46) | JAK2JAK3JAK1CDK4CDK6 | |
| SCHEMBL12371745 | 1.00 | JAK2 (0.46) | JAK2JAK3JAK1CDK4CDK6 | |
| SCHEMBL13608449 | 1.00 | JAK2 (0.46) | JAK2JAK3JAK1CDK4CDK6 | |
| SCHEMBL12371733 | 1.00 | JAK2 (0.46) | JAK2JAK3JAK1CDK4CDK6 | |
| SCHEMBL13608444 | 0.95 | JAK2 (0.44) | JAK2JAK3JAK1CDK4CDK6 | |
| SCHEMBL12371793 | 0.95 | JAK2 (0.47) | JAK2JAK3JAK1CDK4CDK6 | |
| SCHEMBL13608426 | 0.86 | JAK2 (0.42) | JAK2JAK3JAK1CDK4CDK6 | |
| SCHEMBL13608448 | 0.86 | JAK2 (0.42) | JAK2JAK3JAK1CDK4CDK6 | |
| SCHEMBL13608308 | 0.85 | JAK2 (0.44) | JAK2JAK3JAK1CDK4CDK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989459-B2 | Protein kinase C (PKC); rheumatoid arthritis, lupus, transplant rejection, asthma, inflammatory bowel disease, cancer and diabetes; for example, 2-(pyrrolidin-3-ylmethylamino)-9-(2-trifluoromethoxybenzyl)-7,8-dihydro-9H-purin-8-one | PHARMACOPEIA, LLC (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989459-B2 | Protein kinase C (PKC); rheumatoid arthritis, lupus, transplant rejection, asthma, inflammatory bowel disease, cancer and diabetes; for example, 2-(pyrrolidin-3-ylmethylamino)-9-(2-trifluoromethoxybenzyl)-7,8-dihydro-9H-purin-8-one | PHARMACOPEIA, LLC (US) | 2011-08-02 | — | — | US | disclosed |
| US-20080085909-A1 | Purinones and 1H-imidazopyridinones as PKC-theta inhibitors | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2008-04-10 | — | — | US | disclosed |
| US-20080085909-A1 | Purinones and 1H-imidazopyridinones as PKC-theta inhibitors | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085909-A1 | Purinones and 1H-imidazopyridinones as PKC-theta inhibitors | PRKCE, PRKCH, PRKCQ | JAK2 735/4885JAK3 719/4885JAK1 645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.